Kaneka Logo
About the LIPOSORBER System

Indications for Use

The LIPOSORBER® LA-15 System is approved by the FDA and indicated for use in performing low density lipoprotein cholesterol (LDL-C) apheresis to acutely remove LDL-C from the plasma of the following high risk patient populations for whom diet has been ineffective and maximum drug therapy has either been ineffective or not tolerated:

They are patients with:

  • Functional Hypercholesterolemic Heterozygotes with LDL-C ≥ 160 mg/dL and either documented coronary heart disease or documented peripheral arterial disease.

  • Functional Hypercholesterolemic Heterozygotes with LDL-C ≥ 300mg/dL, or

  • Functional Hypercholesterolemic Homozygotes with LDL-C >500 mg/dL

Treatment Frequency

For patients with an LDL-C between 160 to 300 mg/dl, LIPOSORBER treatment should be performed once every two weeks. For patients with LDL-C ≥ 300 mg/dl, treatments should be weekly.


© Copyright Kaneka Pharma America, LLC . All rights reserved.

The information on this site is intended for U.S. residents only.